A perspective on 99mTc and 125/131I labeled receptor targeted compounds and their in vitro/in vivo affinities |
| |
| Authors: | F. Zumrut Biber Muftuler Perihan Unak |
| |
| Affiliation: | 1.Labeled Compounds Department,Hot Labs Center, Atomic Energy Authority,Cairo,Egypt;2.Applied Organic Chemistry Department, Organic Chemical Industries Division,National Research Center,Cairo,Egypt |
| |
| Abstract: | A novel quinoline derivative, 2,2′-[(5-chloro-8-hydroxyquinoline-7-yl) methylazanediyl] diacetic acid (CHQMADA) was labeled with 99mTc using SnCl2·2H2O as a reducing agent to give a complex with a labeling yield 94 %. Also [99mTc(H2O)3(CO)3]+ was prepared by heating at 100 °C for 30 min using 2 mg CHQMADA at pH 8 to give a labeling yield >99 %. 99mTc-(CO)3 CHQMADA and 99mTc-Sn(II)-CHQMADA showed tissue uptake (target to non target T/NT = 6.80 ± 0.22) and (T/NT = 5.65 ± 0.34) respectively in Escherichia coli induced infection, which is higher than the commercially available 99mTc-ciprofloxacin (T/NT = 3.80 ± 0.80). In conclusion, both complexes were able to differentiate between septic and aseptic inflammation with superiority of [99mTc-(CO)3 CHQMADA]. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
